Skip to main content
SpringerLink
Log in

Fortschritte in der Diagnostik der Natalizumab-assoziierten PML?

  • Literatur kompakt
  • Published:
DNP - Der Neurologe und Psychiater Aims and scope

Der Einsatz der hoch wirksamen immunmodulatorischen Therapie mit Natalizumab in der MS-Therapie wird hauptsächlich durch das Auftreten der PML limitiert. Die bessere Kenntnis von Biomarkern zur Risikoevaluation und die frühzeitige Diagnostik sind wesentliche Forschungsinhalte.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Warnke C et al. Cerebrospinal Fluid JC Virus Antibody Index for Diagnosis of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. Ann Neurol 2014; Epub ahead of print. doi: 10.1002/ana.24153.

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Martin Marziniak

Authors
  1. Martin Marziniak
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marziniak, M. Fortschritte in der Diagnostik der Natalizumab-assoziierten PML?. DNP 15, 28 (2014). https://doi.org/10.1007/s15202-014-0962-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15202-014-0962-z

Search

Navigation